Cargando…

Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine

A paradigm-shift in the management of non-small cell lung cancer (NSCLC) has resulted in many new therapies becoming available for patients with advanced disease. Stratification of treatment by histologic and molecular subtype is recommended to obtain the greatest clinical benefit for patients while...

Descripción completa

Detalles Bibliográficos
Autores principales:	Graham, Donna M., Leighl, Natasha B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2014
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4170132/ https://www.ncbi.nlm.nih.gov/pubmed/25295228 http://dx.doi.org/10.3389/fonc.2014.00258

Ejemplares similares

Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine
por: Soldera, Sara Victoria, et al.
Publicado: (2017)

Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC
por: Zer, Alona, et al.
Publicado: (2014)

Editorial: Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine
por: Melosky, Barbara
Publicado: (2017)

The Treatment of Metastatic Non-Small Cell Lung Cancer in a New Era of Personalized Medicine
por: Hirsh, Vera
Publicado: (2015)

Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS
por: Korpanty, Grzegorz J., et al.
Publicado: (2014)

Recent Advances in Immunotherapy in Metastatic NSCLC
por: Bansal, Pranshu, et al.
Publicado: (2016)

Artificial Intelligence in the Management of Glioma: Era of Personalized Medicine
por: Sotoudeh, Houman, et al.
Publicado: (2019)

Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients
por: Patel, Yuti P., et al.
Publicado: (2021)

Current State of Personalized Genitourinary Cancer Radiotherapy in the Era of Precision Medicine
por: Kamran, Sophia C., et al.
Publicado: (2021)

Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
por: Blais, Normand, et al.
Publicado: (2014)

Review of EGFR TKIs in Metastatic NSCLC, Including Ongoing Trials
por: Melosky, Barbara
Publicado: (2014)

Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC
por: Bansal, Pranshu, et al.
Publicado: (2016)

Editorial: An era of personalized medicine in breast cancer: integrating artificial intelligence into practice
por: Masood, Nosheen, et al.
Publicado: (2023)

Impact of Phosphoproteomics in the Era of Precision Medicine for Prostate Cancer
por: Ramroop, Johnny R., et al.
Publicado: (2018)

Editorial: Update on the Biology, Management, and Treatment of Small Cell Lung Cancer
por: Puri, Sonam, et al.
Publicado: (2020)

Economic Analysis of Tissue-First, Plasma-First, and Complementary NGS Approaches for Treatment-Naïve Metastatic Lung Adenocarcinoma
por: Yang, Szu-Chun, et al.
Publicado: (2022)

Erratum: Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
Publicado: (2014)

Antiangiogenesis for Advanced Non-Small-Cell Lung Cancer in the Era of Immunotherapy and Personalized Medicine
por: Tabchi, Samer, et al.
Publicado: (2017)

Heterogeneity of tumour mutational burden in metastatic NSCLC demonstrated by endobronchial ultrasound sampling
por: Leong, Tracy L., et al.
Publicado: (2023)

Personal Neoantigens From Patients With NSCLC Induce Efficient Antitumor Responses
por: Zhang, Wei, et al.
Publicado: (2021)

IMRT in the treatment of locally advanced or inoperable NSCLC in the pre-durvalumab era: clinical outcomes and pattern of relapses, experience from the Oscar Lambret Center
por: Le Roy, Thomas, et al.
Publicado: (2023)

RNA Sequencing for Personalized Treatment of Metastatic Leiomyosarcoma: Case Report
por: Seryakov, Alexander, et al.
Publicado: (2021)

Diagnostics and treatment of ovarian cancer in the era of precision medicine - opportunities and challenges
por: Bukłaho, Patrycja Aleksandra, et al.
Publicado: (2023)

Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR–TKIs
por: Melosky, Barbara, et al.
Publicado: (2014)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

Clinical and Economic Impact of Upfront Next-Generation Sequencing for Metastatic NSCLC in East Asia
por: Loong, Herbert H., et al.
Publicado: (2022)

Chemo-immunotherapy for metastatic non-squamous NSCLC in a patient with HIV infection: A case report
por: Inno, Alessandro, et al.
Publicado: (2023)

Tissue MicroRNA Expression as a Predictor of Response to Immunotherapy in NSCLC Patients
por: Grenda, Anna, et al.
Publicado: (2021)

Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies
por: Wenzel, Mike, et al.
Publicado: (2021)

Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US
por: Chen, Jigang, et al.
Publicado: (2021)

Pembrolizumab-combination therapy for previously untreated metastatic nonsquamous NSCLC: Real-world outcomes at US oncology practices
por: Liu, Stephen V., et al.
Publicado: (2022)

Advances in Personalized Targeted Treatment of Metastatic Melanoma and Non-Invasive Tumor Monitoring
por: Klinac, Dragana, et al.
Publicado: (2013)

Metabolites as Prognostic Markers for Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Platinum-Doublet Chemotherapy
por: Hao, Desirée, et al.
Publicado: (2020)

Mechanisms and Implications of CDK4/6 Inhibitors for the Treatment of NSCLC
por: Zhang, Jinmeng, et al.
Publicado: (2021)

Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment
por: Helgadottir, Hildur, et al.
Publicado: (2018)

A New Era of Prostate Cancer Precision Medicine
por: Malik, Adil, et al.
Publicado: (2019)

Targeting Pyrimidine Metabolism in the Era of Precision Cancer Medicine
por: Wang, Wanyan, et al.
Publicado: (2021)

The Era of Radiogenomics in Precision Medicine: An Emerging Approach to Support Diagnosis, Treatment Decisions, and Prognostication in Oncology
por: Shui, Lin, et al.
Publicado: (2021)

Biliary Tract Cancers: Treatment Updates and Future Directions in the Era of Precision Medicine and Immuno-Oncology
por: Manne, Ashish, et al.
Publicado: (2021)

Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer
por: Barnes, Tristan A., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rev7n0tbunuqj9l4tlf6gdjdve